Karolinska Institutet

Quince Therapeutics appointed Dr. Hassan Abolhassani, a top-cited immunologist from Karolinska Institutet, to its Scientific Advisory Board as the ninth expert member.

A Swedish population study of 247,420 individuals found that ADHD medications consistently reduced risks of self-harm, unintentional injury, traffic crashes, and crime across all age groups and sexes.

A randomized controlled trial of 161 patients with major depressive disorder and obesity found that adding simvastatin to escitalopram provided no additional antidepressant benefits compared to placebo.

A 13-week randomized trial of 384 patients with moderate to severe alcohol use disorder found that combining varenicline and bupropion produced approximately twice the effect of currently available medications.

Alamar Biosciences has announced a strategic collaboration with Sweden's SciLifeLab to advance translational proteomics and accelerate biomarker discovery for early disease detection.

A comprehensive meta-analysis of five randomized controlled trials confirms belimumab's superior efficacy over placebo in treating systemic lupus erythematosus (SLE) according to BICLA criteria.

The ten-year partnership between Johnson & Johnson Innovative Medicine and Karolinska Institutet has yielded significant scientific advances across nine disease areas, with researchers working side by side since 2015.

The global nanorobots for drug delivery market is projected to grow from $1.22 billion in 2025 to $1.73 billion by 2030, representing a CAGR of 7.05% as demand for targeted therapeutic solutions increases.

New research from Karolinska Institutet demonstrates that Biovica's DiviTum® TKa blood test, when combined with inflammation protein biomarkers, significantly improves prediction of immunotherapy efficacy in melanoma patients.

Researchers at Karolinska Institutet discovered that children's tumors are less inflammatory and have fewer mutations than adults', explaining their reduced response to immunotherapy treatments.